| Q49887083 | Activity of the PI3K-δ,γ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma |
| Q33930795 | Advances in kinase inhibition: treating rheumatic diseases and beyond |
| Q51079342 | Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ. |
| Q38611244 | B cell receptor signaling regulates metabolism in Chronic Lymphocytic Leukemia |
| Q38708600 | Breakthrough therapies in B-cell non-Hodgkin lymphoma. |
| Q33659691 | Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies. |
| Q37113544 | Chronic lymphocytic leukemia therapy: new targeted therapies on the way |
| Q37587308 | Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy |
| Q47898168 | Combination therapy with the type II anti-CD20 antibody obinutuzumab. |
| Q91973253 | Converging TLR9 and PI3Kgamma signaling induces sterile inflammation and organ damage |
| Q58729853 | Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib |
| Q46430396 | Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases |
| Q41064013 | Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate |
| Q41992697 | Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors |
| Q51738230 | Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration. |
| Q39065374 | Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). |
| Q58697794 | Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study |
| Q91826752 | Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases |
| Q39226787 | Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia |
| Q38882332 | Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells |
| Q38344404 | Emerging drugs for diffuse large B-cell lymphoma |
| Q38543771 | Emerging immunological drugs for chronic lymphocytic leukemia |
| Q89777371 | Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia |
| Q38261144 | Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings |
| Q33749652 | Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells |
| Q41680129 | Fisetin targets phosphatidylinositol-3-kinase and induces apoptosis of human B lymphoma Raji cells |
| Q93003265 | High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions |
| Q34636880 | IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells |
| Q34529311 | Idelalisib in the management of lymphoma. |
| Q38221107 | Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment. |
| Q92758418 | Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor |
| Q34356481 | In search of magic bullets: the golden age of immunotherapeutics. |
| Q90634708 | Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma |
| Q38193070 | Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies |
| Q52653219 | Kinase inhibitors: the road ahead. |
| Q38882099 | Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. |
| Q42514844 | Metabolically active CD4+ T cells expressing Glut1 and OX40 preferentially harbor HIV during in vitro infection |
| Q60949513 | Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis |
| Q92731408 | Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells |
| Q38192725 | Molecular abnormalities of the B cell in systemic lupus erythematosus are candidates for functional inhibition treatments. |
| Q38666875 | Molecules in medicine mini-review: isoforms of PI3K in biology and disease |
| Q38756064 | Novel approaches to the management of noneosinophilic asthma |
| Q41974388 | Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. |
| Q35060792 | PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. |
| Q30080017 | PI3K and cancer: lessons, challenges and opportunities |
| Q38532898 | PI3K inhibitors in inflammation, autoimmunity and cancer. |
| Q35833018 | PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. |
| Q41994564 | PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma |
| Q26774768 | Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas |
| Q26774771 | Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas |
| Q38848941 | Petri Net computational modelling of Langerhans cell Interferon Regulatory Factor Network predicts their role in T cell activation |
| Q35958056 | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia |
| Q26779129 | Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia |
| Q48019225 | Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches |
| Q52880677 | Platelet-Derived Growth Factor Receptor Activation Promotes the Prodestructive Invadosome-Forming Phenotype of Synoviocytes from Patients with Rheumatoid Arthritis. |
| Q42378867 | Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ. |
| Q99549141 | Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review |
| Q36240848 | Signal transduction and chemotaxis in mast cells |
| Q39413866 | Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases |
| Q64098996 | Structural Determinants of Isoform Selectivity in PI3K Inhibitors |
| Q37694044 | Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis |
| Q38975656 | Targeting B cells in treatment of autoimmunity |
| Q38218127 | Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment. |
| Q38744922 | Targeting of B-cell receptor signalling in B-cell malignancies. |
| Q26823575 | Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts |
| Q35727453 | Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms |
| Q31070331 | The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date |
| Q33855380 | The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation |
| Q57024599 | The phase 3 DUO trial: duvelisib versus ofatumumab in relapsed and refractory CLL/SLL |
| Q64880506 | The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies. |
| Q36021849 | The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. |
| Q39268911 | Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF). |
| Q64958039 | Treatment Outcomes of Novel Targeted Agents in Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-Analysis. |
| Q38708002 | Upcoming Therapeutic Targets in Cutaneous Lupus Erythematous |
| Q27334428 | p110γ/δ Double-Deficiency Induces Eosinophilia and IgE Production but Protects from OVA-Induced Airway Inflammation |